Spleen News and Research

RSS

JAK2 inhibitor ruxolitinib shows promise in treating CMML patients

Chronic myelomonocytic leukemia (CMML) is a rare type of myelodysplastic, myeloproliferative neoplasm characterized by increased numbers of peripheral monocytes and less than 20 percent blasts. CMML has few treatment options and patients only survive on average for 12 to 24 months.

29 May 2015

Microfluidic cell-squeezing device could introduce specific antigens inside immune system's B cells

MIT researchers have shown that they can use a microfluidic cell-squeezing device to introduce specific antigens inside the immune system's B cells, providing a new approach to developing and implementing antigen-presenting cell vaccines.

22 May 2015

GHIT Fund expands investments in leishmaniasis, diagnostic tests

The Global Health Innovative Technology Fund, which in the last two years has funded almost $32 million for innovative tools to tackle global infectious diseases, today announced additional investments of nearly $11 million that bring its portfolio to approximately $43 million.

22 May 2015

Nanoparticle-based therapy effective in treating mice with multiple myeloma

Researchers have designed a nanoparticle-based therapy that is effective in treating mice with multiple myeloma, a cancer of immune cells in the bone marrow.

21 May 2015

TSRI researchers find interferon beta protein as prime suspect in persistent viral infections

Interferon proteins are normally considered virus-fighters, but scientists at The Scripps Research Institute have found evidence that one of them, interferon beta (IFNβ), has an immune-suppressing effect that can help some viruses establish persistent infections.

14 May 2015

Major breakthrough in understanding development of type 1 diabetes

Joslin researchers have uncovered the action of a gene that regulates the education of T cells, providing insight into how and why the immune system begins mistaking the body's own tissues for targets. The gene, Clec16a, is one of a suite of genes associated with multiple autoimmune disorders, suggesting it is fundamental to the development of autoimmunity.

13 May 2015

Australian researchers discover rogue germinal centre B cells that trigger autoimmune disease

Australian researchers believe they have discovered a group of cells that trigger autoimmune disease, as well as the molecular 'trigger guard' that normally holds them in check.

13 May 2015

Noninvasive nuclear medicine test can help determine effectiveness of aromatase inhibitor treatment

A new, noninvasive nuclear medicine test can be used to determine whether aromatase inhibitor treatment will be effective for specific cancer patients, according to a recent study reported in The Journal of Nuclear Medicine.

8 May 2015

Researchers pinpoint new mechanism responsible for malaria progression

A team of researchers from four universities has pinpointed one of the mechanisms responsible for the progression of malaria, providing a new target for possible treatments.

28 Apr 2015

Data from pacritinib Phase 3 PERSIST-1 trial in patients with myelofibrosis to be highlighted at ASCO

CTI BioPharma Corp. and Baxter International Inc. today announced that data from the randomized Phase 3 PERSIST-1 trial evaluating the investigational agent pacritinib in patients with myelofibrosis will be highlighted in a late-breaking oral presentation at the upcoming American Society of Clinical Oncology 2015 Meeting (May 29-June 2, 2015 in Chicago, Ill).

From Baxter International Inc. 22 Apr 2015

Results of pacritinib Phase 2 study in myelofibrosis patients published in journal 'Blood'

CTI BioPharma Corp. today announced that results of a Phase 2 study of pacritinib, in patients with myelofibrosis were published in the journal Blood. Pacritinib is a next-generation oral JAK2/FLT3 multikinase inhibitor currently in Phase 3 development in the PERSIST program.

16 Mar 2015

Recruitment completed for Phase III PROUD-PV trial of P1101 for treatment of polycythemia vera

PharmaEssentia (Taipei, Taiwan) and AOP Orphan (Vienna, Austria) announce the completion of recruitment for the Phase III trial PROUD-PV to support global marketing of P1101 (Ropeginterferon alfa-2b), a novel, long-acting, mono-pegylated interferon for the first line treatment of polycythemia vera.

11 Mar 2015

Pacritinib for myelofibrosis meets primary endpoint in Phase 3 PERSIST-1 trial

CTI BioPharma Corp. and Baxter International Inc. today announced positive top-line results for the primary endpoint from PERSIST-1, the randomized, controlled Phase 3 registration clinical trial examining pacritinib, a next generation oral JAK2/FLT3 multikinase inhibitor, for the treatment of patients with primary or secondary myelofibrosis.

From Baxter International Inc. 9 Mar 2015

Eliglustat drug improves liver, spleen size and hemoglobin level in adults with Gaucher disease type 1

Among previously untreated adults with Gaucher disease type 1, a genetic disease in which there is improper metabolism due to a defect in an enzyme, treatment with the drug eliglustat resulted in significant improvements in liver and spleen size hemoglobin level, and platelet count, according to a study in the February 17 issue of JAMA.

18 Feb 2015

Study shows amyloid formation may link type 2 diabetes and Alzheimer disease

The pathological process amyloidosis, in which misfolded proteins (amyloids) form insoluble fibril deposits, occurs in many diseases, including Alzheimer disease (AD) and type 2 diabetes mellitus (T2D).

17 Feb 2015

Researchers develop novel strategy in fight against cancer

A team of researchers led by Associate Professor Caroline Lee from the Yong Loo Lin School of Medicine at the National University of Singapore, in collaboration with Associate Professor Song Jianxing of the Department of Biological Sciences at the NUS Faculty of Science, has developed a novel strategy in the fight against cancer.

15 Feb 2015

Spleen News and Research

JAK2 inhibitor ruxolitinib shows promise in treating CMML patients

Microfluidic cell-squeezing device could introduce specific antigens inside immune system's B cells

GHIT Fund expands investments in leishmaniasis, diagnostic tests

Nanoparticle-based therapy effective in treating mice with multiple myeloma

TSRI researchers find interferon beta protein as prime suspect in persistent viral infections

Major breakthrough in understanding development of type 1 diabetes

Australian researchers discover rogue germinal centre B cells that trigger autoimmune disease

Noninvasive nuclear medicine test can help determine effectiveness of aromatase inhibitor treatment

Researchers pinpoint new mechanism responsible for malaria progression

Data from pacritinib Phase 3 PERSIST-1 trial in patients with myelofibrosis to be highlighted at ASCO

Results of pacritinib Phase 2 study in myelofibrosis patients published in journal 'Blood'

Recruitment completed for Phase III PROUD-PV trial of P1101 for treatment of polycythemia vera

Pacritinib for myelofibrosis meets primary endpoint in Phase 3 PERSIST-1 trial

Eliglustat drug improves liver, spleen size and hemoglobin level in adults with Gaucher disease type 1

Study shows amyloid formation may link type 2 diabetes and Alzheimer disease

Researchers develop novel strategy in fight against cancer

Farnesoid-X receptor could play key role in hepatobiliary and gastrointestinal disorders

Researchers reveal link between the microbiome of young mice and later onset of autoimmune disease

CML mouse model reveals previously unreported facets of disease

Low alcohol consumption, plant-based diet reduce risk of obesity-related cancers

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News